Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment

Maria Del Ben, Mario Fabiani, Lorenzo Loffredo, Licia Polimeni, Roberto Carnevale, Francesco Baratta, Marco Brunori, Fabiana Albanese, Teresa Augelletti, Francesco Violi, Francesco Angelico, Maria Del Ben, Mario Fabiani, Lorenzo Loffredo, Licia Polimeni, Roberto Carnevale, Francesco Baratta, Marco Brunori, Fabiana Albanese, Teresa Augelletti, Francesco Violi, Francesco Angelico

Abstract

Background: Several studies suggest an increase of oxidative stress and a reduction of endothelial function in obstructive sleep apnoea syndrome (OSAS). We assessed the association between OSAS, endothelial dysfunction and oxidative stress. Further aim was to evaluate the effect of nasal continuous positive airway pressure (nCPAP) on oxidative stress and arterial dysfunction.

Methods: We studied 138 consecutive patients with heavy snoring and possible OSAS. Patients underwent unattended overnight home polysomnography. Ten patients with severe OSAS were revaluated after 6 months of nCPAP therapy. To assess oxidative stress in vivo, we measured urinary 8-iso-PGF2α and serum levels of soluble NOX2-derived peptide (sNOX2-dp). Serum levels of nitrite/nitrate (NOx) were also determined. Flow-mediated brachial artery dilation (FMD) was measured to asses endothelial function.

Results: Patients with severe OSAS had higher urinary 8-iso-PGF2α (p<0.001) and serum NOX2 and lower NOx. A negative association was observed between FMD and OSA severity. Apnea/hypopnea index was significantly correlated with the indices of central obesity and with urinary 8-isoprostanes (r=0.298, p<0.001). The metabolic syndrome (t=-4.63, p<0.001) and urinary 8-isoprostanes (t=-2.02, p<0.05) were the only independent predictors of FMD. After 6-months nCPAP treatment, a significant decrease of serum NOX2, (p<0.005) and urinary 8-iso-PGF2α (p<0.01) was observed, while serum NOx showed only a minor increase. A statistically significant increase of FMD was observed (from 3.6% to 7.0%).

Conclusions: The results of our study indicate that patients with OSAS and cardiometabolic comorbidities have increased oxidative stress and arterial dysfunction that are partially reversed by nCPAP treatment.

References

    1. Remmers JE, deGroot WJ, Sauerland EK, Anch AM. Pathogenesis of upper airway occlusion during sleep. J Appl Physiol. 1978;44:931–938.
    1. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnoea: implications for cardiac and vascular disease. JAMA. 2003;290:1906–1914. doi: 10.1001/jama.290.14.1906.
    1. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol. 2003;41:1429–1437. doi: 10.1016/S0735-1097(03)00184-0.
    1. Angelico F, Del Ben M, Augelletti T. et al.Obstructive sleep apnoea syndrome and the metabolic syndrome in an internal medicine setting. Eur J Intern Med. 2010;21:191–195. doi: 10.1016/j.ejim.2010.03.006.
    1. Suzuki YJ, Jain V, Park AM, Day RM. Oxidative stress and oxidant signaling in obstructive sleep apnea and associated cardiovascular diseases. Free Radic Biol Med. 2006;40:1683–1692. doi: 10.1016/j.freeradbiomed.2006.01.008.
    1. Lee SD, Ju G, Choi JA, Kim JW, Yoon IY. The association of oxidative stress with central obesity in obstructive sleep apnea. Sleep Breath. 2011;16:511–517.
    1. Barceló A, Miralles C, Barbé F, Vila M, Pons S, Agustí AG. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J. 2000;16:644–647. doi: 10.1034/j.1399-3003.2000.16d13.x.
    1. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep. 2004;27:123–128.
    1. Katsoulis K, Kontakiotis T, Spanogiannis D. Total antioxidant status in patients with obstructive sleep apnea without comorbidities: the role of the severity of the disease. Sleep Breath. 2011;15:861–866. doi: 10.1007/s11325-010-0456-y.
    1. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ. 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest. 2003;124:1386–1392. doi: 10.1378/chest.124.4.1386.
    1. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011;364:656–665. doi: 10.1056/NEJMra0910283.
    1. Ohike Y, Kozaki K, Iijima K. et al.Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure-possible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circ J. 2005;69:221–226. doi: 10.1253/circj.69.221.
    1. Ip MS, Lam B, Chan LY. et al.Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med. 2000;162:2166–2171.
    1. Joannides R, Haefeli WE, Linder L. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314–1319. doi: 10.1161/01.CIR.91.5.1314.
    1. Cooke JP. Flow, NO and atherogenesis. ProcNatlAcadSci U S A. 2003;100:768–770. doi: 10.1073/pnas.0430082100.
    1. Corretti MC, Anderson TJ, Benjamin EJ. et al.Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–265.
    1. Chung S, Yoon IY, Shin YK. et al.Endothelial dysfunction and C-reactive protein in relation with the severity of obstructive sleep apnea syndrome. Sleep. 2007;30:997–1001.
    1. Nieto FJ, Herrington DM, Redline S, Benjamin EJ, Robbins JA. Sleep apnea and markers of vascular endothelial function in a large community sample of older adults. Am J Respir Crit Care Med. 2004;169:354–360.
    1. Oflaz H, Cuhadaroglu C, Pamukcu B. et al.Endothelial function in patients with obstructive sleep apnea syndrome but without hypertension. Respiration. 2006;73:751–756. doi: 10.1159/000094183.
    1. Chung S, Yoon IY, Lee CH, Kim JW. The association of nocturnal hypoxemia with arterial stiffness and endothelial dysfunction in male patients with obstructive sleep apnea syndrome. Respiration. 2010;79:363–369. doi: 10.1159/000228905.
    1. Chung S. Endothelial dysfunction and inflammatory reactions of eldery and middle aged men with obstructive sleep apnea syndrome. Sleep Breath. 2009;13:11–17. doi: 10.1007/s11325-008-0210-x.
    1. Duchna HW, Stoohs R, Guilleminault C. et al.Vascular endothelial dysfunction in patients with mild obstructive sleep apnea syndrome. Wien Med Wochenschr. 2006;156:596–604. doi: 10.1007/s10354-006-0341-2.
    1. Jurado-Gámez B, Fernandez-Marin MC, Gómez-Chaparro JL. et al.Relationship of oxidative stress and endothelial dysfunction in sleep apnoea. Eur Respir J. 2011;37:873–879. doi: 10.1183/09031936.00027910.
    1. Fleetham J, Ayas N, Bradley D. CTS Sleep Disordered Breathing Committee et al.Canadian Thoracic Society guidelines: diagnosis and treatment of sleep disordered breathing in adults. Can Respir J. 2006;13:387–392.
    1. Christou K, Kostikas K, Pastaka C, Tanou K, Antoniadou I, Gourgoulianis KI. Nasal continuous positive airway pressure treatment reduces systemic oxidative stress in patients with severe obstructive sleep apnea syndrome. Sleep Med. 2009;10:87–94. doi: 10.1016/j.sleep.2007.10.011.
    1. Büchner NJ, Quack I, Woznowski M, Stähle C, Wenzel U, Rump LC. Microvascular endothelial dysfunction in obstructive sleep apnea is caused by oxidative stress and improved by continuous positive airway pressure therapy. Respiration. 2011;82:409–417. doi: 10.1159/000323266.
    1. Murri M, Alcázar-Ramírez J, Garrido-Sánchez L. et al.Oxidative stress and metabolic changes after continuous positive airway pressure treatment according to previous metabolic disorders in sleep apnea-hypopnea syndrome patients. Transl Res. 2009;3:111–121.
    1. Hernandez C, Abreu J, Abreu P, Colino R, Jimenez. Effects of nasal positive airway pressure treatment on oxidative stress in patients with sleep apnea-hypopnea sindrome. Arch Bronconeumol. 2006;42:125–126.
    1. Jelic S, Padeletti M, Kawut SM. et al.Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation. 2008;117:2270–2278. doi: 10.1161/CIRCULATIONAHA.107.741512.
    1. Comondore VR, Cheema R, Fox J. et al.The impact of CPAP on cardiovascular biomarkers in minimally symptomatic patients with obstructive sleep apnea: a pilot feasibility randomized crossover trial. Lung. 2009;187:17–22. doi: 10.1007/s00408-008-9115-5.
    1. Bayram NA, Ciftci B, Keles T. et al.Endothelial function in normotensive men with obstructive sleep apnea before and 6 months after CPAP treatment. Sleep. 2009;32:1257–1263.
    1. Ciccone MM, Favale S, Scicchitano P. et al.Reversibility of the endothelial dysfunction after CPAP therapy in OSAS patients. Int J Cardiol. 2011;158:383–386.
    1. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2007;176:706–712. doi: 10.1164/rccm.200703-500OC.
    1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469–480.
    1. Pignatelli P, Carnevale R, Cangemi R. et al.Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. ArteriosclerThrombVascBiol. 2010;30:360–367.
    1. Wang Z, Ciabattoni G, Créminon C. et al.Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther. 1995;275:94–100.
    1. Praticò D. Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis. 2008;201:8–16. doi: 10.1016/j.atherosclerosis.2008.04.037.
    1. Cave AC, Brewer AC, Narayanapanicker A. et al.NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal. 2006;8:691–728. doi: 10.1089/ars.2006.8.691.
    1. Yamauchi M, Nakano H, Maekawa J. et al.Oxidative stress in obstructive sleep apnea. Chest. 2005;127:1674–1679. doi: 10.1378/chest.127.5.1674.
    1. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J RespirCrit Care Med. 2002;165:934–939.
    1. Wali SO, Bahammam AS, Massaeli H. et al.Susceptibility of LDL to oxidative stress in obstructive sleep apnea. Sleep. 1998;21:290–296.
    1. Svatikova A, Wolk R, Lerman LO. et al.Oxidative stress in obstructive sleep apnoea. Eur Heart J. 2005;26:2435–2439. doi: 10.1093/eurheartj/ehi440.
    1. Grebe M, Eisele HJ, Weissmann N. et al.Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J RespirCrit Care Med. 2006;173:897–901. doi: 10.1164/rccm.200508-1223OC.
    1. Kato M, Roberts-Thomson P, Phillips BG. et al.Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation. 2000;102:2607–2610. doi: 10.1161/01.CIR.102.21.2607.
    1. Chung S, Yoon IY, Lee CH, Kim JW. The effects of nasal continuous positive airway pressure on vascular functions and serum cardiovascular risk factors in obstructive sleep apnea syndrome. Sleep Breath. 2011;15:71–76. doi: 10.1007/s11325-009-0323-x.
    1. Ip MS, Tse HF, Lam B, Tsang KW, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. Am J RespirCrit Care Med. 2004;169:348–353.
    1. Angelico F, Loffredo L, Pignatelli P. et al.Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. Intern Emerg Med. 2011;7:219–227.
    1. Jelic S, Lederer DJ, Adams T. et al.Vascular inflammation in obesity and sleep apnea. Circulation. 2010;121:1014–1021. doi: 10.1161/CIRCULATIONAHA.109.900357.
    1. Zhan G, Serrano F, Fenik P. et al.NADPH oxidase mediates hypersomnolence and brain oxidative injury in a murine model of sleep apnea. Am J RespirCrit Care Med. 2005;172:921–929. doi: 10.1164/rccm.200504-581OC.
    1. Dingli K, Coleman EL, Vennelle M. et al.Evaluation of a portable device for diagnosing the sleep apnoea/hypopnoea syndrome. EurRespir J. 2003;21:253–259.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera